Rezolute Inc. has published a document detailing preliminary patient demographics and baseline characteristics from the Phase 3 sunRIZE study of Ersodetug for hypoglycemia due to congenital hyperinsulinism. The document outlines the trial's progress, including the randomized, double-blind design, treatment arms, and interim analysis results. The study focuses on assessing the efficacy of Ersodetug in treating this rare pediatric condition. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief on July 14, 2025, and is solely responsible for the information contained therein.